首页> 外文期刊>Neuromuscular disorders: NMD >197th ENMC international workshop: Neuromuscular disorders of mitochondrial fusion and fission - OPA1 and MFN2 molecular mechanisms and therapeutic strategies. 26-28 April 2013, Naarden, The Netherlands.
【24h】

197th ENMC international workshop: Neuromuscular disorders of mitochondrial fusion and fission - OPA1 and MFN2 molecular mechanisms and therapeutic strategies. 26-28 April 2013, Naarden, The Netherlands.

机译:第197届ENMC国际研讨会:线粒体融合和裂变的神经肌肉疾病-OPA1和MFN2分子机制和治疗策略。 2013年4月26日至28日,荷兰纳尔登。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The 197th ENMC workshop entitled "Neuromuscular disorders of mitochondrial fusion and fission - OPA1 and MFN2 molecular mechanisms and therapeutic strategies" took place from the 26th to the 28th of April 2013 in Naarden, The Netherlands. A multidisciplinary group of 19 participants took part in this workshop, including 18 clinical and basic science researchers from six different countries (France, Germany, Italy, Spain, the United Kingdom (UK), and the United States of America), and one patient representative from CMT UK. The principal aim of this workshop was to establish an integrated research network in order to better understand the basic mechanisms responsible for the development of neuromuscular disease in patients harbouring pathogenic OPA1 and MFN2 mutations, which cause autosomal dominant optic atrophy (DOA) and axonal Charcot-Marie-Tooth disease (CMT2A), respectively [1,2].
机译:2013年4月26日至28日,第197届ENMC研讨会题为“线粒体融合和裂变的神经肌肉疾病-OPA1和MFN2分子机制与治疗策略”。一个由19名参与者组成的多学科小组参加了该研讨会,其中包括来自六个不同国家(法国,德国,意大利,西班牙,英国(英国)和美利坚合众国)的18名临床和基础科学研究人员,其中一名患者英国CMT代表。该研讨会的主要目的是建立一个综合的研究网络,以便更好地了解导致病原性OPA1和MFN2突变的患者发生神经肌肉疾病的基本机制,这些突变导致常染色体显性视神经萎缩(DOA)和轴突性夏科-玛丽牙齿疾病(CMT2A)分别[1,2]。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号